1760 related articles for article (PubMed ID: 32024970)
1. CD8
van der Leun AM; Thommen DS; Schumacher TN
Nat Rev Cancer; 2020 Apr; 20(4):218-232. PubMed ID: 32024970
[TBL] [Abstract][Full Text] [Related]
2. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral CD8
Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
[TBL] [Abstract][Full Text] [Related]
4. Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.
Pasetto A; Gros A; Robbins PF; Deniger DC; Prickett TD; Matus-Nicodemos R; Douek DC; Howie B; Robins H; Parkhurst MR; Gartner J; Trebska-McGowan K; Crystal JS; Rosenberg SA
Cancer Immunol Res; 2016 Sep; 4(9):734-43. PubMed ID: 27354337
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
Linette GP; Carreno BM
Curr Hematol Malig Rep; 2019 Aug; 14(4):286-291. PubMed ID: 31187421
[TBL] [Abstract][Full Text] [Related]
6. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion.
Shakiba M; Zumbo P; Espinosa-Carrasco G; Menocal L; Dündar F; Carson SE; Bruno EM; Sanchez-Rivera FJ; Lowe SW; Camara S; Koche RP; Reuter VP; Socci ND; Whitlock B; Tamzalit F; Huse M; Hellmann MD; Wells DK; Defranoux NA; Betel D; Philip M; Schietinger A
J Exp Med; 2022 Feb; 219(2):. PubMed ID: 34935874
[TBL] [Abstract][Full Text] [Related]
7. Tissue-Resident Memory T Cells in Cancer Immunosurveillance.
Park SL; Gebhardt T; Mackay LK
Trends Immunol; 2019 Aug; 40(8):735-747. PubMed ID: 31255505
[TBL] [Abstract][Full Text] [Related]
8. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
9. Endometrial Cancer Suppresses CD8+ T Cell-Mediated Cytotoxicity in Postmenopausal Women.
Patel MV; Shen Z; Rodriguez-Garcia M; Usherwood EJ; Tafe LJ; Wira CR
Front Immunol; 2021; 12():657326. PubMed ID: 33968059
[TBL] [Abstract][Full Text] [Related]
10. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.
Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY
Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856
[TBL] [Abstract][Full Text] [Related]
11. B7H4 expression in tumor cells impairs CD8 T cell responses and tumor immunity.
Zhou L; Ruan M; Liu Y; Zhu Y; Fu D; Wu K; Zhang Q
Cancer Immunol Immunother; 2020 Feb; 69(2):163-174. PubMed ID: 31848656
[TBL] [Abstract][Full Text] [Related]
12. Decreased level of peripheral CD8
Li Y; Qian T; Zhao H; Zhang Z; Ming Y; Qiao G; Liu J
Future Oncol; 2020 Nov; 16(32):2611-2617. PubMed ID: 32820651
[No Abstract] [Full Text] [Related]
13. Bystander CD8
Simoni Y; Becht E; Fehlings M; Loh CY; Koo SL; Teng KWW; Yeong JPS; Nahar R; Zhang T; Kared H; Duan K; Ang N; Poidinger M; Lee YY; Larbi A; Khng AJ; Tan E; Fu C; Mathew R; Teo M; Lim WT; Toh CK; Ong BH; Koh T; Hillmer AM; Takano A; Lim TKH; Tan EH; Zhai W; Tan DSW; Tan IB; Newell EW
Nature; 2018 May; 557(7706):575-579. PubMed ID: 29769722
[TBL] [Abstract][Full Text] [Related]
14. Memory CD8
Han J; Khatwani N; Searles TG; Turk MJ; Angeles CV
Semin Immunol; 2020 Jun; 49():101435. PubMed ID: 33272898
[TBL] [Abstract][Full Text] [Related]
15. Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma.
Yan M; Hu J; Ping Y; Xu L; Liao G; Jiang Z; Pang B; Sun S; Zhang Y; Xiao Y; Li X
Front Immunol; 2021; 12():758288. PubMed ID: 34804045
[TBL] [Abstract][Full Text] [Related]
16. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Sobral-Leite M; Salomon I; Opdam M; Kruger DT; Beelen KJ; van der Noort V; van Vlierberghe RLP; Blok EJ; Giardiello D; Sanders J; Van de Vijver K; Horlings HM; Kuppen PJK; Linn SC; Schmidt MK; Kok M
Breast Cancer Res; 2019 Aug; 21(1):90. PubMed ID: 31391067
[TBL] [Abstract][Full Text] [Related]
17. Chromatin states define tumour-specific T cell dysfunction and reprogramming.
Philip M; Fairchild L; Sun L; Horste EL; Camara S; Shakiba M; Scott AC; Viale A; Lauer P; Merghoub T; Hellmann MD; Wolchok JD; Leslie CS; Schietinger A
Nature; 2017 May; 545(7655):452-456. PubMed ID: 28514453
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
19. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]